Analisis Kemurnian Radiokimia Radiofarmaka 99mTc-TRODAT-1 Berdasarkan Evaluasi Kromatografi Lapis Tipis pada Tiga Kelompok Eksperimen

Frandy Putra Perdamen Tarigan; Kharisma Perdani K

doi:10.69693/ijim.v4i2.985

Authors

Frandy Putra Perdamen Tarigan Universitas Padjadjaran
Kharisma Perdani K RSUP Dr. Hasan Sadikin, Bandung

DOI:

https://doi.org/10.69693/ijim.v4i2.985

Keywords:

99mTc-TRODAT-1, Kemurnian Radiokimia, Kendali Mutu, Parkinson

Abstract

Radiofarmaka 99mTc-TRODAT-1 merupakan agen pencitraan molekuler Single Photon Emission Computed Tomography yang sangat spesifik untuk mengevaluasi integritas neuron dopaminergik presinaptik melalui ikatan dengan dopamine transporter (DAT). Uji kendali mutu berupa penentuan kemurnian radiokimia (Radiochemical Purity) merupakan tahapan krusial untuk menjamin efikasi pencitraan dan meminimalkan paparan radiasi non-spesifik pada pasien. Penelitian ini bertujuan untuk menganalisis variabilitas kemurnian radiokimia dari tiga kelompok eksperimen formulasi 99mTc-TRODAT-1 menggunakan kromatografi lapis tipis yang dipindai dengan radio-TLC scanner MiniGITA. Metode pemisahan menggunakan sistem fase diam berbasis silika gel dengan fase gerak kombinasi aseton dan NaCl. Hasil eksperimen menunjukkan variabilitas yang signifikan antar-batch: Eksperimen 1 (06/02/2025) menghasilkan RCP sebesar 79,87% (tidak memenuhi syarat); Eksperimen 2 (18/07/2025) menghasilkan pemisahan resolusi tinggi dengan kadar kompleks aktif 95,32%, perteknetat bebas (99mTcO4-) 3,67%, dan koloid 99mTcO2 1,01%; sedangkan Eksperimen 3 (22/01/2026) menunjukkan kemurnian tertinggi sebesar 95,40%. Disimpulkan bahwa optimasi parameter formulasi seperti pH, jumlah reduktor SnCl2, dan waktu inkubasi sangat mempengaruhi keberhasilan radiolabeling, di mana kadar RCP ≥ 90% menjadi prasyarat mutlak sebelum aplikasi klinis pada pasien Parkinson.

Downloads

Download data is not yet available.

References

Antonini, A., Benti, R., De Notaris, R., Tesei, S., Zecchinelli, A., Sacilotto, G., & Pezzoli, G. (2003). 123I-FP-CIT SPECT imaging in early Parkinson’s disease. Journal of Neural Transmission, 110(7), 767–776.

Benamer, H. T. S., Patterson, J., Wyper, D. J., et al. (2000). Differentiation of parkinsonism and essential tremor using DAT SPECT. Movement Disorders, 15(3), 503–510.

Bhatia, K. P., Bain, P., Bajaj, N., Elble, R., Hallett, M., Louis, E. D., & Deuschl, G. (2018). Consensus statement on the classification of tremors. Movement Disorders, 33(1), 75–87.

Booij, J., Tissingh, G., Boer, G. J., Speelman, J. D., Stoof, J. C., Janssen, A. G., & Wolters, E. C. (1997). Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy volunteers and patients with Parkinson’s disease. Journal of Nuclear Medicine, 38(12), 1879–1884.

Booij, J., & Knol, R. J. J. (2007). SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism & Related Disorders, 13(Suppl 3), S425–S428.

Brooks, D. J. (2010). Imaging approaches to Parkinson disease. Journal of Nuclear Medicine, 51(4), 596–609.

Burn, D. J., & O’Brien, J. T. (2003). Use of functional imaging in Parkinsonian syndromes. Journal of Neurology, Neurosurgery & Psychiatry, 74(9), 1223–1229.

Catafau, A. M., & Tolosa, E. (2004). Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders, 19(10), 1175–1182.

Cherry, S. R., Sorenson, J. A., & Phelps, M. E. (2012). Physics in Nuclear Medicine (4th ed.). Elsevier Saunders.

Darcourt, J., Booij, J., Tatsch, K., et al. (2010). EANM procedure guidelines for brain neurotransmission SPECT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 37(2), 443–450.

Eshuis, S. A., Maguire, R. P., Leenders, K. L., Jonkman, S., Jager, P. L., & van Waarde, A. (2009). Comparison of FP-CIT SPECT with F-DOPA PET in Parkinson’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 36(3), 454–462.

Fahn, S., & Sulzer, D. (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx, 1(1), 139–154.

Huang, W. S., Lin, S. Z., Lin, J. C., Wey, S. P., Ting, G., & Liu, R. S. (2001). Evaluation of early-stage Parkinson’s disease with 99mTc-TRODAT-1 imaging. Journal of Nuclear Medicine, 42(9), 1303–1308.

IAEA. (2014). Nuclear Medicine Physics: A Handbook for Teachers and Students. Vienna: International Atomic Energy Agency.

Jankovic, J. (2008). Parkinson’s disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368–376.

Kaasinen, V., & Vahlberg, T. (2017). Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. Annals of Neurology, 82(6), 873–882.

Kim, J. S., Lee, K. S., Kim, Y. K., et al. (2004). Diagnostic value of 99mTc-TRODAT-1 SPECT in Parkinsonian syndromes. Clinical Nuclear Medicine, 29(9), 551–555.

Kuhl, D. E., Koeppe, R. A., & Minoshima, S. (1999). On the importance of parkinsonism in PET and SPECT imaging. Journal of Nuclear Medicine, 40(6), 1003–1005.

Kung, M. P., Stevenson, D. A., Plossl, K., Meegalla, S. K., & Kung, H. F. (1997). 99mTc-TRODAT-1 dopamine transporter imaging agent. European Journal of Nuclear Medicine, 24(4), 372–380.

Langston, J. W. (2006). The Parkinson’s complex: Parkinsonism is just the tip of the iceberg. Annals of Neurology, 59(4), 591–596.

Marek, K., Innis, R., van Dyck, C., et al. (2001). Imaging the dopamine transporter: Guidelines for SPECT imaging. Movement Disorders, 16(4), 436–447.

Mozley, P. D., Schneider, J. S., Acton, P. D., et al. (2000). Binding of 99mTc-TRODAT-1 to dopamine transporters in Parkinson’s disease and healthy subjects. Journal of Nuclear Medicine, 41(4), 584–589.

Poewe, W., Seppi, K., Tanner, C. M., et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.

Postuma, R. B., Berg, D., Stern, M., et al. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601.

Ravina, B., Marek, K., Eberly, S., et al. (2005). Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease. Movement Disorders, 20(7), 807–814.

Saha, G. B. (2010). Fundamentals of Nuclear Pharmacy (6th ed.). Springer.

Seibyl, J. P., Marek, K. L., Sheff, K., et al. (1997). Test-retest reproducibility of dopamine transporter SPECT imaging. Journal of Nuclear Medicine, 38(9), 1453–1459.

Vallabhajosula, S., Zimmerman, R. E., Picard, M., et al. (1998). Technetium-99m-labeled tropane derivative for dopamine transporter imaging. Journal of Nuclear Medicine, 39(4), 652–656.

Varrone, A., Halldin, C., & Farde, L. (2013). New developments of dopaminergic imaging in Parkinson’s disease. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 57(1), 68–82.

Winogrodzka, A., Booij, J., Wolters, E. Ch., Stoof, J. C., & Berendse, H. W. (2003). Disease-related and drug-induced changes in dopamine transporter imaging. European Journal of Nuclear Medicine, 30(4), 603–614.

Ziebell, M., Andersen, B. B., Thomsen, G., et al. (2012). Predictive value of dopamine transporter imaging in uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 39(2), 242–249.